Jae‐Lyun Lee

2004–2025 年に発表

別表記: Jae-Lyun Lee · Jae-lyun Lee

112: 論文数
20,328: 被引用数
58: h 指数
108: i10 指数

被引用数

引用元

国・地域

0%21.5%その他 24.5%

機関

分野

トピック

全論文

並び替え

検索で開く

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
著者: Thomas Powles, Jonathan E. Rosenberg, Guru Sonpavde, Yohann Loriot, Ignacio Durán, Jae‐Lyun Lee, Nobuaki Matsubara, Christof Vulsteke, Daniel Castellano, Chunzhang Wu, Mary S. Campbell, Maria Matsangou, Daniel P. Petrylak - New England Journal of Medicine 2021 被引用: 1,155
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
著者: Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin - New England Journal of Medicine 2017 被引用: 3,390
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
著者: David S. Hong, Yoon‐Koo Kang, Mitesh J. Borad, Jasgit C. Sachdev, Samuel Ejadi, Ho Yeong Lim, Andrew Brenner, Keunchil Park, Jae‐Lyun Lee, Tae‐You Kim, SangJoon Shin, Carlos Becerra, Gerald S. Falchook, Jay Stoudemire, Desiree Martin, Kevin Kelnar, Heidi J. Peltier, Vinícius Bonato, Andreas G. Bader, Susan Smith, Sinil Kim, Vincent O’Neill, Muhammad Shaalan Beg - British Journal of Cancer 2020 被引用: 912
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
著者: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Yen‐Hwa Chang, Jaroslav Hájek, Stefan N. Symeonides, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Howard Gurney, Christine Chevreau, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, John M. Burke, Gurjyot K. Doshi, Delphine Topart, Stéphane Oudard, Hans J. Hammers, Hiroshi Kitamura, Jens Bedke, Rodolfo F. Perini, Pingye Zhang, Kentaro Imai, Jaqueline Willemann-Rogerio, David I. Quinn, Thomas Powles - New England Journal of Medicine 2021 被引用: 746
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
著者: Brian I. Rini, Thomas Powles, Michael B. Atkins, Bernard Escudier, David F. McDermott, Cristina Suárez, Sergio Bracarda, Walter M. Stadler, Frede Donskov, Jae‐Lyun Lee, Robert D. Hawkins, Alain Ravaud, B. Yа. Alekseev, Michael Staehler, Motohide Uemura, Ugo De Giorgi, Begoña Mellado, Camillo Porta, Bohuslav Melichar, Howard Gurney, Jens Bedke, Toni K. Choueiri, Francis Parnis, Tarik Khaznadar, Alpa Thobhani, Shi Li, Elisabeth Piault‐Louis, Gretchen Frantz, Mahrukh Huseni, Christina Schiff, Marjorie C. Green, Robert J. Motzer - The Lancet 2019 被引用: 1,010
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
著者: Robert J. Motzer, Paul B. Robbins, Thomas Powles, Laurence Albigès, John B.A.G. Haanen, James Larkin, Xinmeng Jasmine Mu, Keith A. Ching, Motohide Uemura, Sumanta K. Pal, B. Yа. Alekseev, Gwénaëlle Gravis, Matthew T. Campbell, Konstantin Penkov, Jae‐Lyun Lee, Subramanian Hariharan, Xiao Wang, Weidong Zhang, Jing Wang, Aleksander Chudnovsky, Alessandra di Pietro, Amber C. Donahue, Toni K. Choueiri - Nature Medicine 2020 被引用: 522
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
著者: Thomas Powles, Michiel S. van der Heijden, Daniel Castellano, Matthew D. Galsky, Yohann Loriot, Daniel P. Petrylak, Osamu Ogawa, Se Hoon Park, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J. Eigl, Howard Gurney, Som D. Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P. Fay, Ignacio Durán, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok Gupta, Wendy J. Levin, Joaquim Bellmunt, Se Hoon Park, Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli ほか 127 名 - The Lancet Oncology 2020 被引用: 498
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
著者: Evan Y. Yu, Daniel P. Petrylak, Peter H. O’Donnell, Jae‐Lyun Lee, Michiel S. van der Heijden, Yohann Loriot, Mark N. Stein, Andrea Necchi, Takahiro Kojima, Michael R. Harrison, Se Hoon Park, David I. Quinn, Elisabeth I. Heath, Jonathan E. Rosenberg, Joyce Steinberg, Shang-Ying Liang, Janet Trowbridge, Mary S. Campbell, Bradley A. McGregor, Arjun Vasant Balar - The Lancet Oncology 2021 被引用: 267
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
著者: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Yen-Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Naomi B. Haas, Howard Gurney, Piotr Sawrycki, Mauricio Mahave, Marine Gross‐Goupil, Tian Zhang, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, Stéphane Oudard, Delphine Topart, Hans J. Hammers, Hiroshi Kitamura, David F. McDermott, Adriano da Silva, Eric Winquist, Jerry Cornell, Aymen Elfiky, Joseph E. Burgents, Rodolfo F. Perini, Thomas Powles - New England Journal of Medicine 2024 被引用: 285
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
著者: Toni K. Choueiri, Bernard Escudier, Thomas Powles, Nizar M. Tannir, Paul N. Mainwaring, Brian I. Rini, Hans J. Hammers, Frede Donskov, Bruce J. Roth, Katriina Peltola, Jae‐Lyun Lee, Daniel Y.C. Heng, Manuela Schmidinger, Neeraj Agarwal, Cora N. Sternberg, David F. McDermott, Dana T. Aftab, Colin Hessel, Christian Scheffold, Gisela Schwab, Thomas E. Hutson, Sumanta K. Pal, Robert J. Motzer - The Lancet Oncology 2016 被引用: 939
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
著者: Thomas Powles, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Howard Gurney, Yen‐Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Joseph E. Burgents, Lei Xu, Kentaro Imai, David I. Quinn, Toni K. Choueiri, Piotr Tomczak, Toni K. Choueiri, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Jaroslav Hájek, Tzu-Ping Lin, Stefan N. Symeonides, Jae‐Lyun Lee, Piotr Sawrycki, Naomi B. Haas, Howard Gurney, Mauricio Mahave, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Christine Chevreau, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Delphine Topart, Stéphane Oudard, Evgeniy Kopyltsov, H. Hammers, David I. Quinn, Ajjai Alva, Juliana de Menezes, Adriano Gonçalves e Silva, Eric Winquist, Alketa Hamzaj, Giuseppe Procopio, Boguslawa Karaszewska, Ewa M. Nowakowska-Zajdel, B. Yа. Alekseev, Rustem Gafanov, А. А. Измайлов, Andrey Semenov, S. G. Afanasyev, Oleg Lipatov, T.B. Powles, Sandy Srinivas, David F. McDermott, Samith T. Kochuparambil, Ian D. Davis, Katriina Peltola, Roberto Sabbatini, Jinsoo Chung, М. I. Shkolnik, В. Б. Матвеев, P. Gajate Borau, Steven McCune, Thomas E. Hutson, Alejandro Dri, Silvio Correia Sales, Carrie Yeung, Carmen Marcela Alcala Castro, Peter J. Boström, Brigitte Laguerre, Consuelo Buttigliero, Ugo De Giorgi, Eugeniy A. Fomin, Yousef Zakharia, Clara Hwang, Eric A. Singer, Jeffrey T. Yorio, David Waterhouse, Rubén Dario Kowalyszyn, Margarita Sonia Alfie, Eduardo Yañez Ruiz, Tomáš Büchler, Krista Kankaanranta, G. Ferretti, Go Kimura, Kazuo Nishimura, Naoya Masumori, Satoshi Tamada, Haruaki Kato, Hiroshi Kitamura, Iwona Danielewicz ほか 133 名 - The Lancet Oncology 2022 被引用: 278
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
著者: Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Sang Joon Shin, Jae‐Lyun Lee, Niven Mehra, Ray McDermott, Núria Sala‐González, Peter C.C. Fong, Richard Greil, Margitta Retz, Juan Pablo Sade, Patricio Yañez, Eric Yi‐Hsiu Huang, Stephen Begbie, Rustem Gafanov, Maria De Santis, Eli Rosenbaum, Michael Kolinsky, Felipe Rey, Kun‐Yuan Chiu, Guilhem Roubaud, Gero Kramer, Makoto Sumitomo, Francesco Massari, Hiroyoshi Suzuki, Ping Qiu, Jinchun Zhang, Jeri Kim, Christian Poehlein, Evan Y. Yu - Journal of Clinical Oncology 2023 被引用: 132
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
著者: Toni K. Choueiri, Bernard Escudier, Thomas Powles, Paul N. Mainwaring, Brian I. Rini, Frede Donskov, Hans J. Hammers, Thomas E. Hutson, Jae‐Lyun Lee, Katriina Peltola, Bruce J. Roth, Georg A. Bjarnason, Lajos Géczi, Bhumsuk Keam, Pablo Maroto, Daniel Y.C. Heng, Manuela Schmidinger, Philip W. Kantoff, Anne E. Borgman-Hagey, Colin Hessel, Christian Scheffold, Gisela Schwab, Nizar M. Tannir, Robert J. Motzer - New England Journal of Medicine 2015 被引用: 1,226
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
著者: David F. McDermott, Jae‐Lyun Lee, Marek Ziobro, Cristina Suárez, Przemysław Langiewicz, В. Б. Матвеев, Paweł Wiechno, Rustem Gafanov, Piotr Tomczak, Frédéric Pouliot, Frede Donskov, B. Yа. Alekseev, Sang Joon Shin, Georg A. Bjarnason, Daniel Castellano, Rachel Kloss Silverman, Rodolfo F. Perini, Charles Schloss, Michael B. Atkins - Journal of Clinical Oncology 2021 被引用: 287
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival
著者: Shaan Dudani, Guillermo de Velasco, J. Connor Wells, Chun Loo Gan, Frede Donskov, Camillo Porta, Anna Paola Fraccon, Felice Pasini, Jae‐Lyun Lee, Aaron R. Hansen, Georg A. Bjarnason, Benoit Beuselinck, Sumanta K. Pal, Takeshi Yuasa, Nils Kroeger, Ravindran Kanesvaran, M. Neil Reaume, Christina Canil, Toni K. Choueiri, Daniel Y.C. Heng - JAMA Network Open 2021 被引用: 299
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
著者: William K. Kelly, Daniel C. Danila, Chia‐Chi Lin, Jae‐Lyun Lee, Nobuaki Matsubara, Patrick J. Ward, Andrew J. Armstrong, David Pook, Miso Kim, Tanya B. Dorff, Stefanie Fischer, Yung‐Chang Lin, Lisa G. Horvath, Christopher Sumey, Zhao Yang, Gabor Jurida, Kristen M. Smith, Jamie N. Connarn, Hweixian Leong Penny, Julia Stieglmaier, Leonard J. Appleman - Cancer Discovery 2023 被引用: 97
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
著者: Laurence Albigès, Howard Gurney, Vagif Atduev, Cristina Suárez, Miguel Ángel Climent, David Pook, Piotr Tomczak, Philippe Barthélémy, Jae‐Lyun Lee, V.P. Stus, Thomas Ferguson, Paweł Wiechno, Erhan Gökmen, Louis Lacombe, Craig Gedye, Rodolfo F. Perini, Manish Sharma, Xiang Peng, Chung‐Han Lee - The Lancet Oncology 2023 被引用: 149
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
著者: Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donás, Robert Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado, Sergei Varlamov, Monika Joshi, Ignacio Durán, Scott T. Tagawa, Yousef Zakharia, Sydney Akapame, Ademi Santiago-Walker, Manish Monga, Anne O’Hagan, Yohann Loriot, Andrea Necchi, Yohann Loriot, Se Hoon Park, Scott T. Tagawa, Aude Fléchon, B. Ya. Alexeev, Sergey Varlamov, Robert Huddart, Earle F. Burgess, Arash Rezazadeh, Arlene O. Siefker‐Radtke, Yann Vano, Donatello Gasparro, Alketa Hamzaj, Eugeniy Kopyltsov, Jesus Gracia Donas, Begoña Mellado, Omi Parikh, Peter Schatteman, Stéphane Culine, Nadine Houédé, Sylvie Zanetta, Gaetano Facchini, Giorgio V. Scagliotti, Giovanni Schinzari, Jae‐Lyun Lee, Mikhail Shkolnik, Mark T. Fleming, Monika Joshi, Peter H. O’Donnell, Herbert Stöger, Karel Decaestecker, Luc Dirix, Jean Pascal Machiels, Dephine Borchiellini, R. Delva, Frédéric Rolland, Boris Hadaschik, Margitta Retz, Eli Rosenbaum, Umberto Basso, Alessandra Mosca, Hyo Jin Lee, Dong Bok Shin, C. Cebotaru, Ignacio Durán, Víctor Moreno, José Luis Perez‐Gracia, Álvaro Pinto, Wen-Pin Su, Shian‐Shiang Wang, John D. Hainsworth, Ian D. Schnadig, Sandhya Srinivas, Nicholas J. Vogelzang, Wolfgang Loidl, Johannes Meran, M. Gross Goupil, Florence Joly, Florian Imkamp, Theodor Klotz, S. Krege, Matthias May, Wolfgang Schultze-Seemann, Arne Strauß, Uwe Zimmermann, Daniel Keizman, Avivit Peer, Avishai Sella, Rossana Berardi, Ugo De Giorgi, Cora N. Sternberg, Sun Young Rha, Iurie Bulat, А. А. Измайлов, Vsevolod Matveev, Vladimir Vladimirov, Joan Carles, Albert Font, M.I. Sáez, Isabel Syndikus ほか 6 名 - The Lancet Oncology 2022 被引用: 169
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
著者: Thomas Powles, Peter H. O’Donnell, Christophe Massard, Hendrik-Tobias Arkenau, Terence W. Friedlander, Christopher Hoimes, Jae‐Lyun Lee, Michael Ong, Srikala S. Sridhar, Nicholas J. Vogelzang, Mayer Fishman, Jingsong Zhang, Sandy Srinivas, Jigar Parikh, Joyce Antal, Xiaoping Jin, Ashok Gupta, Yong Ben, Noah M. Hahn - JAMA Oncology 2017 被引用: 846
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
著者: Toni K. Choueiri, Thomas Powles, Katriina Peltola, Guillermo de Velasco, Mauricio Burotto, Cristina Suárez, Pooja Ghatalia, Roberto Iacovelli, Elaine T. Lam, Elena Verzoni, Mahmut Gümüş, Walter M. Stadler, Christian Kollmannsberger, Bohuslav Melichar, Balaji Venugopal, Marine Gross‐Goupil, Alexandr Poprach, Maria De Santis, Fabio A. Schutz, Se Hoon Park, Dmitry Nosov, Camillo Porta, Jae‐Lyun Lee, Xavier García del Muro, Elisa Biscaldi, Ray Manneh Kopp, Mototsugu Oya, He Li, Aobo Wang, Rodolfo F. Perini, Donna Vickery, Laurence Albigès, Brian I. Rini - New England Journal of Medicine 2024 被引用: 142
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
著者: Robert J. Motzer, Thomas Powles, Michael B. Atkins, Bernard Escudier, David F. McDermott, B. Yа. Alekseev, Jae‐Lyun Lee, Cristina Suárez, Daniil Stroyakovskiy, Ugo De Giorgi, Frede Donskov, Begoña Mellado, Romain Banchereau, Habib Hamidi, Omara Khan, Veronica Craine, Mahrukh Huseni, Nick Flinn, Sarita Dubey, Brian I. Rini - JAMA Oncology 2021 被引用: 163
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression
著者: Cora N. Sternberg, Daniel P. Petrylak, Joaquim Bellmunt, Hiroyuki Nishiyama, Andrea Necchi, Howard Gurney, Jae‐Lyun Lee, Michiel S. van der Heijden, Eli Rosenbaum, Nicolas Penel, See‐Tong Pang, Jian‐Ri Li, Xavier García del Muro, Florence Joly, Zsuzsanna Pápai, Weichao Bao, Peter Ellinghaus, Chengxing Lu, Mitchell Robert Sierecki, Sabine Coppieters, Keiko Nakajima, Tatiane Cristine Ishida, David I. Quinn - Journal of Clinical Oncology 2022 被引用: 94
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
著者: Sumanta K. Pal, Jonathan E. Rosenberg, Jean Hoffman‐Censits, Raanan Berger, David I. Quinn, Matthew D. Galsky, Juergen Wolf, Christian Dittrich, Bhumsuk Keam, Jean‐Pierre Delord, Jan H.M. Schellens, Gwénaëlle Gravis, Jacques Médioni, Pablo Maroto, Virote Sriuranpong, Chaiyut Charoentum, Howard A. Burris, Viktor Grünwald, Daniel P. Petrylak, Ulka N. Vaishampayan, Eliahu Gez, Ugo De Giorgi, Jae‐Lyun Lee, Jens Voortman, Sumati Gupta, Sunil Sharma, Amir Mortazavi, David J. Vaughn, Randi Isaacs, Katie Parker, Xueying Chen, Kun Yu, Dale Porter, Diana Graus Porta, Dean F. Bajorin - Cancer Discovery 2018 被引用: 257
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
著者: Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, Bram Estes, Gregory L. Moore, Matthew J. Bernett, Umesh S. Muchhal, John R. Desjarlais, Binnaz K. Staley, Jennitte Stevens, Keegan S. Cooke, Famke Aeffner, Thomas Oliver, Julia Stieglmaier, Jae‐Lyun Lee, Angela Coxon, Julie M. Bailis - Cancer Discovery 2023 被引用: 46